Although antibodies against EGFR and HER2 are used to treat cancer, only some patients respond and resistance often emerges. Jacobsen and colleagues present in this issue experimental evidence favoring replacement of the currently applied monoclonal antibodies with oligoclonal mixtures of six synergistic antibodies, simultaneously engaging EGFR, HER2, and also HER3. Clin Cancer Res; 21(18); 4030–2. ©2015 AACR.
See related article by Jacobsen et al., p. 4110
By Yarden, Y., Sela, M.